XML 51 R26.htm IDEA: XBRL DOCUMENT

Related-Party Transactions	12 Months Ended
Related-Party Transactions	Dec. 31, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions In September 2021, the Company entered into a sublease with Sonoma, with whom the Company has common stockholders with board seats, whereby the Company agreed to sublease approximately 18,000 square feet of space in South San Francisco, California currently leased by the Company. Dr. Klausner, the Chair of the Company’s board of directors, also serves as a member of the board of directors of Sonoma. As a part of the sublease, a $4.6 million tenant improvement contribution payment was made by Sonoma, which is recognized over the term of the sublease. As of December 31, 2022 and 2021, there were accrued liabilities and other current liabilities of $0.5 million and $0.5 million, respectively, and other non-current liabilities of $3.5 million and $4.0 million, respectively, in connection with the sublease with Sonoma. Income of $2.6 million and $1.8 million was recognized in other operating income, net for the years ended December 31, 2022 and 2021, respectively, of which $1.9 million and $0.6 million was attributed to sublease income for the years ended December 31, 2022 and 2021, respectively. See Note 9, Leases, for more detail on the Sonoma sublease. The Company was party to the GSK Agreement, who is a holder of more than 10% of the Company’s outstanding common stock. See Note 3, License, Collaboration, and Success Payment Agreements. Deferred revenue of zero and $5.0 million as of December 31, 2022 and 2021, respectively, and deferred revenue, non-current of zero and $79.7 million as of December 31, 2022 and 2021, respectively, were in connection with the GSK Agreement. Revenue recognized in connection with the GSK agreement was $84.7 million, $10.5 million and $7.8 million for the years ended December 31, 2022, 2021 and 2020, respectively. GSK terminated the GSK Agreement effective December 24, 2022. See Note 3, License, Collaboration, and Success Payment Agreements, for additional details regarding the termination of the GSK Agreement. In March 2020, the Company repurchased 546,806 shares of its Series A convertible preferred stock and 2,032,166 shares of its common stock from a related party. See Note 10, Convertible Preferred Stock and Note 11, Stockholders’ Equity.